Drugs / LY4101174
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06238479 | Mar 2024 → Mar 2027 expected | cervical cancer, esophageal cancer, head and neck squamous cell carcinoma, malignant pancreatic neoplasm +7 | Eli Lilly and Company | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4101174 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06238479 ↗ |
| Route | Intravenous | “administered intravenously (IV).” NCT06238479 ↗ |